晚期三阴性乳腺癌一线化疗GP与NP方案的疗效对比

Comparison of efficacy of GP versus NP as first-line chemotherapy for advanced triple-negative breast cancer

目的对比晚期三阴性乳腺癌一线化疗GP(吉西他滨+顺铂)与NP(长春瑞滨+顺铂)方案的疗效。方法84例晚期三阴性乳腺癌患者,按随机数字表法分为对照组和观察组,各42例。对照组患者采用GP(吉西他滨+顺铂)方案进行治疗,观察组患者采用NP(长春瑞滨+顺铂)方案进行治疗。对比两组临床疗效以及治疗后毒副反应发生情况。结果治疗后,观察组和对照组的总有效率均为42.86%,对比无差异(P>0.05)。治疗后,观察组贫血、脱发、肝功能受损、血小板减少、恶心呕吐、白细胞减少发生率分别为30.95%、28.57%、33.33%、33.33%、61.90%、66.67%,对照组分别为28.57%、30.95%、33.33%、33.33%、59.52%、71.43%,对比无差异(P>0.05)。结论晚期三阴性乳腺癌一线化疗GP与NP方案的疗效与治疗安全性均较佳,且无明显差异,均可作为晚期三阴性乳腺癌的首选治疗方案,临床可根据患者实际情况进行选择。

Objective To compare the efficacy of GP(gemcitabine+cisplatin)versus NP(vinorelbine+cisplatin)as first-line chemotherapy for advanced triple-negative breast cancer.Methods 84 patients with advanced triple-negative breast cancer were randomly divided into a control group and an observation group according to the random numerical table,with 42 cases in each group.The clinical efficacy and incidence of toxic side effects after treatment were compared between the two groups.Results After treatment,the total effective rate of the observation group and the control group was both 42.86%,and there was no difference in comparison(P>0.05).After treatment,the incidence of anemia,alopecia,impaired liver function,thrombocytopenia,nausea and vomiting,and leukopenia in the observation group were 30.95%,28.57%,33.33%,33.33%,61.90%,and 66.67%,and those in the control group were 28.57%,30.95%,33.33%,33.33%,59.52%,and 71.43%,and there was no difference in comparison(P>0.05).Conclusion Both GP and NP as first-line chemotherapy for advanced triple-negative breast cancer has better efficacy and treatment safety,and have no significant differences,which can be used as the first choice of treatment for advanced triple-negative breast cancer.These two regimens can be selected clinically according to the actual situation of patients.